CG Oncology (CGON) Expected to Announce Earnings on Tuesday

CG Oncology (NASDAQ:CGON) is projected to post its quarterly earnings results before the market opens on Tuesday, March 25th. Analysts expect CG Oncology to post earnings of ($0.37) per share and revenue of $0.11 million for the quarter.

CG Oncology Trading Down 0.5 %

Shares of CG Oncology stock opened at $27.67 on Tuesday. CG Oncology has a 52-week low of $23.91 and a 52-week high of $46.99. The company has a 50 day moving average of $28.32 and a 200 day moving average of $32.40.

Insider Transactions at CG Oncology

In other news, Director Leonard E. Post sold 1,000 shares of the company’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $29.66, for a total transaction of $29,660.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of CG Oncology in a research note on Friday, January 10th. Morgan Stanley reiterated an “overweight” rating and issued a $55.00 price target on shares of CG Oncology in a research note on Friday, March 7th. TD Cowen assumed coverage on shares of CG Oncology in a research note on Tuesday, January 7th. They issued a “buy” rating for the company. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $66.00 price target on shares of CG Oncology in a research note on Friday, December 6th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $63.88.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.